Pasar al contenido principal

NODOS DE REPETIDORES CUANTICOS DE ALTO RENDIMIENTO

PRE2020-095721

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de Promoción del Talento y su Empleabilidad en I+D+i
Subprograma Subprograma Estatal de Formación
Convocatoria Contratos Predoctorales
Año convocatoria 2020
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario INSTITUTO DE CIENCIAS FOTONICAS

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

TANGO1 inhibitors reduce collagen secretion and limit tissue scarring

  • Raote, Ishier
  • Häkkinen, Hanna-Maria
  • Vibe, Carine
  • Broadbent, Katrina
  • Carolis, Carlo
  • Ruprecht, Verena
  • Malhotra, Vivek
Uncontrolled secretion of ECM proteins, such as collagen, can lead to excessive scarring and fibrosis and compromise tissue function. Despite the widespread occurrence of fibrotic diseases and scarring, effective therapies are lacking. A promising approach would be to limit the amount of collagen released from hyperactive fibroblasts. We have designed membrane permeant peptide inhibitors that specifically target the primary interface between TANGO1 and cTAGE5, an interaction that is required for collagen export from endoplasmic reticulum exit sites (ERES). Application of the peptide inhibitors leads to reduced TANGO1 and cTAGE5 protein levels and a corresponding inhibition in the secretion of several ECM components, including collagens. Peptide inhibitor treatment in zebrafish results in altered tissue architecture and reduced granulation tissue formation during cutaneous wound healing. The inhibitors reduce secretion of several ECM proteins, including collagens, fibrillin and fibronectin in human dermal fibroblasts and in cells obtained from patients with a generalized fibrotic disease (scleroderma). Taken together, targeted interference of the TANGO1-cTAGE5 binding interface could enable therapeutic modulation of ERES function in ECM hypersecretion, during wound healing and fibrotic processes., The authors thank the CRG Advanced Light Microscopy Unit (ALMU), the Protein Technologies Unit, and the CRG/UPF Flow Cytometry Unit. Susanne Neumann (Cologne) provided excellent technical assistance. We would like to thank Prof. Dr. Pia Moinzadeh for obtaining the skin biopsies. The authors acknowledge the support of the Spanish Ministry of Science and Innovation to the EMBL partnership, the Centro de Excelencia Severo Ochoa and the CERCA Programme/Generalitat de Catalunya and the Alexander v. Humboldt foundation. We acknowledge financial support from the following sources: Ministerio de Economía y Competitividad (SEV-2012-0208, BFU2013-44188-P, CSD2009-00016 to V.M.); Deutsche Forschungsgemeinschaft (ID 468236352) and CMMC Cologne to T.K and V.M. V.R. acknowledges financial support from the Ministerio de Ciencia y Innovacion through the Plan Nacional (PID2020-117011GB-I00). This project has received funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (grant agreement No 951146). This publication is part of the Project TARTAFI (Ref. PDC2021-121870-I00), funded by MCIN/AEI/10.13039/501100011033 and the European Union “NextGenerationEU”/PRTR. This work was supported by the Fondation pour la Recherche Médicale, (FRM) AJE202210016216 to I.R. M.C, G.C, F.C, J.A, and PL-A acknowledge funding from Fundació CELLEX; Ministerio de Economıa y Competitividad - Severo Ochoa programme for Centres of Excellence in R&D (CEX2019-000910-S); CERCA programme and Laserlab-Europe (871124); Ministerio de Ciencia e Innovación (MCIN/AEI/10.13039/501100011033); and Fondo Social Europeo (PRE2020-095721, M.C). The SLN facility corresponds to a “Grup reconegut 2021 SGR 01456 pel Departament de Recerca i Universitats de la Generalitat de Catalunya”. F.C. acknowledges support from the Government of Spain (RYC-2017–22227, PID2019-106232RB-I00/10.13039/501100011033/110198RB-I00).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

TANGO1 inhibitors reduce collagen secretion and limit tissue scarring

  • Raote, Ishier
  • Häkkinen, Hanna-Maria
  • Vibe, Carine
  • Broadbent, Katrina
  • Carolis, Carlo
  • Ruprecht, Verena
  • Malhotra, Vivek
Uncontrolled secretion of ECM proteins, such as collagen, can lead to excessive scarring and fibrosis and compromise tissue function. Despite the widespread occurrence of fibrotic diseases and scarring, effective therapies are lacking. A promising approach would be to limit the amount of collagen released from hyperactive fibroblasts. We have designed membrane permeant peptide inhibitors that specifically target the primary interface between TANGO1 and cTAGE5, an interaction that is required for collagen export from endoplasmic reticulum exit sites (ERES). Application of the peptide inhibitors leads to reduced TANGO1 and cTAGE5 protein levels and a corresponding inhibition in the secretion of several ECM components, including collagens. Peptide inhibitor treatment in zebrafish results in altered tissue architecture and reduced granulation tissue formation during cutaneous wound healing. The inhibitors reduce secretion of several ECM proteins, including collagens, fibrillin and fibronectin in human dermal fibroblasts and in cells obtained from patients with a generalized fibrotic disease (scleroderma). Taken together, targeted interference of the TANGO1-cTAGE5 binding interface could enable therapeutic modulation of ERES function in ECM hypersecretion, during wound healing and fibrotic processes., The authors thank the CRG Advanced Light Microscopy Unit (ALMU), the Protein Technologies Unit, and the CRG/UPF Flow Cytometry Unit. Susanne Neumann (Cologne) provided excellent technical assistance. We would like to thank Prof. Dr. Pia Moinzadeh for obtaining the skin biopsies. The authors acknowledge the support of the Spanish Ministry of Science and Innovation to the EMBL partnership, the Centro de Excelencia Severo Ochoa and the CERCA Programme/Generalitat de Catalunya and the Alexander v. Humboldt foundation. We acknowledge financial support from the following sources: Ministerio de Economía y Competitividad (SEV-2012-0208, BFU2013-44188-P, CSD2009-00016 to V.M.); Deutsche Forschungsgemeinschaft (ID 468236352) and CMMC Cologne to T.K and V.M. V.R. acknowledges financial support from the Ministerio de Ciencia y Innovacion through the Plan Nacional (PID2020-117011GB-I00). This project has received funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (grant agreement No 951146). This publication is part of the Project TARTAFI (Ref. PDC2021-121870-I00), funded by MCIN/AEI/10.13039/501100011033 and the European Union “NextGenerationEU”/PRTR. This work was supported by the Fondation pour la Recherche Médicale, (FRM) AJE202210016216 to I.R. M.C, G.C, F.C, J.A, and PL-A acknowledge funding from Fundació CELLEX; Ministerio de Economıa y Competitividad - Severo Ochoa programme for Centres of Excellence in R&D (CEX2019-000910-S); CERCA programme and Laserlab-Europe (871124); Ministerio de Ciencia e Innovación (MCIN/AEI/10.13039/501100011033); and Fondo Social Europeo (PRE2020-095721, M.C). The SLN facility corresponds to a “Grup reconegut 2021 SGR 01456 pel Departament de Recerca i Universitats de la Generalitat de Catalunya”. F.C. acknowledges support from the Government of Spain (RYC-2017–22227, PID2019-106232RB-I00/10.13039/501100011033/110198RB-I00).
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Three-photon infrared stimulation of endogenous neuroreceptors in vivo

  • Sortino, Rosalba|||0000-0002-8854-6782
  • Cunquero, Marina|||0000-0001-8093-8186
  • Castro-Olvera, Gustavo|||0000-0001-9843-3581
  • Gelabert, Ricard|||0000-0001-6506-5786
  • Moreno, Miquel|||0000-0002-2784-1307
  • Riefolo, Fabio|||0000-0002-6762-2619
  • Matera, Carlo|||0000-0001-6939-3859
  • Fernàndez-Castillo, Noèlia|||0000-0001-9948-0312
  • Agnetta, Luca
  • Decker, Michael
  • Lluch, José M.|||0000-0002-7536-1869
  • Hernando, Jordi|||0000-0002-1126-4138
  • Loza-Alvarez, Pablo|||0000-0002-3129-1213
  • Gorostiza, Pau|||0000-0002-7268-5577
To interrogate neural circuits and crack their codes, in vivo brain activity imaging must be combined with spatiotemporally precise stimulation in three dimensions using genetic or pharmacological specificity. This challenge requires deep penetration and focusing as provided by infrared light and multiphoton excitation, and has promoted two-photon photopharmacology and optogenetics. However, three-photon brain stimulation in vivo remains to be demonstrated. We report the regulation of neuronal activity in zebrafish larvae by three-photon excitation of a photoswitchable muscarinic agonist at 50 pM, a billion-fold lower concentration than used for uncaging, and with mid-infrared light of 1560 nm, the longest reported photoswitch wavelength. Robust, physiologically relevant photoresponses allow modulating brain activity in wild-type animals with spatiotemporal and pharmacological precision. Computational calculations predict that azobenzene-based ligands have high three-photon absorption cross-section and can be used directly with pulsed infrared light. The expansion of three-photon pharmacology will deeply impact basic neurobiology and neuromodulation phototherapies.